Business Context and Reporting Period
This Form 6-K filing by Genmab A/S, a foreign private issuer, covers the month of February 2025. The report, signed on February 12, 2025, by Anthony Pagano (Executive Vice President & Chief Financial Officer), primarily serves to incorporate the Company Announcement dated February 12, 2025, and the Appendix containing the Genmab A/S Annual Report 2024 by reference into the company's registration statements on Form S-8.
Key Financial Metrics
The provided text is a cover sheet and exhibit index for the Form 6-K filing. It does not contain the actual financial data from the Annual Report 2024 or the Company Announcement. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
Material Changes
The filing text does not provide specific details regarding material changes in financial performance or operations compared to prior periods. The substantive information regarding such changes is located in the referenced Exhibit 99.1 (Company Announcement) and Exhibit 99.1(a) (Annual Report 2024), which are not included in the input text.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided cover sheet. These disclosures are expected to be found within the incorporated Annual Report 2024 and the Company Announcement referenced in the exhibit index.
Investor Verification Checklist
- Verify the full content of the "Company Announcement Dated February 12, 2025" (Exhibit 99.1) for immediate operational updates.
- Review the "Genmab A/S Annual Report 2024" (Exhibit 99.1(a)) for audited financial statements, revenue, and profit metrics.
- Confirm the incorporation by reference status of this filing into the specified Form S-8 registration statements (File Nos. 333-232693, 333-253519, 333-262970, and 333-277273).
- Check for any subsequent filings that may supersede the information contained in this Form 6-K.